Dana-Farber Science Uncovers Differences Between Early-Onset and Average-Age-Onset Colorectal Cancer
Colorectal cancer is on the rise in younger adults and appears to be different from colorectal cancer in older adults. The disease is often more aggressive in young people, and less responsive to treatment.
Now, new research from Dana-Farber Cancer Institute and collaborators has for the first time uncovered novel biological distinctions between early-onset colorectal cancer, defined as diagnosed at or below age 50, and average-onset colorectal cancer, defined as diagnosis over age 50. These findings, published in Nature Medicine, could potentially explain the differences doctors see between these patient groups and give researchers clues about what studies to pursue next to better understand, diagnose and treat early-onset colorectal cancer.
The study, done in collaboration with investigators from the Gene Lay Institute of Immunology and Inflammation and the Broad Institute, found differences in the proportions of cell types in younger patients that may have implications for responsiveness to treatment. They also uncovered differences in gene expression and cell-to-cell communication that could contribute to the aggressive nature of the disease.
“In the clinic, we see that our younger patients may not necessarily have better survival than older patients. Younger patients are also more often diagnosed with metastatic disease,” says co-senior author Kimmie Ng, MD, MPH, director of the Young-Onset Colorectal Cancer Center. “The differences we’ve found in this study provide us with a possible explanation and a basis for future investigations into the mechanisms underlying these observations.”
Colorectal cancer is the leading cause of death from cancer among people under age 50 in the U.S. A better understanding of the molecular underpinnings of early-onset colorectal cancer could lead to improvements in screening and treatment.
A thorough study
To make these discoveries, the team relied on tumor samples donated by young patients treated at the Young-Onset Colorectal Cancer Center at Dana-Farber and samples from older patients in Dana-Farber’s gastrointestinal cancer biobank. The team was able to analyze 189 colorectal tumor samples from patients across eight decades of age, with 20 or more samples representing almost every decade.
“Our dedicated center and its flagship research study, the Beyond CRC Project, gives patients the opportunity to partner with us in this research so that we can do studies like this that will help us get to the bottom of why colorectal cancer is on the rise in young people,” says Ng.
The investigators analyzed tumor samples using single-nucleus RNA sequencing, enabling them to look at gene expression data from individual cells. Gene expression data from individual cells helps researchers understand which cell types are present and what functions they perform.
“This is the largest single-cell atlas of colorectal cancer published to date, with the largest number of young patients under the age of 50,” says Ng. “In addition to having a large number of tumor samples, we also had samples from patients spanning the whole spectrum of age, including people in their 20s and people over 90.”
Previous studies relied on smaller numbers of early-onset colorectal cancer samples. They typically employed bulk sequencing, which lumps genetic material from all cells together and provides limited data about cell types and interactions.
Novel insights
This comprehensive dataset enabled the team to find that tumor samples from younger patients have proportionally more stromal cells and fewer epithelial cells than samples from older patients. This pattern held true regardless of the side of the colon the tumor occurred on, as young-onset colorectal cancers often occur on the left side of the colon or in the rectum.
Stromal cells act as scaffolding around tumors. In other cancers, this scaffolding can shield tumors and block chemotherapy and immune cells from entering the tumor and killing cancer cells.
To validate these findings, the team examined data from other large studies, including the Nurses’ Health Study and the Health Professionals Follow-Up Study. An analysis of 712 colorectal cancer cases showed a similar higher ratio of stromal cells to epithelial cells in younger patients.
“This is the first time this finding has been reported, and it is important because it serves as a guidepost for where to look next,” says Ng. “We need to focus on what the stromal cells are doing and how they are interacting with the tumor microenvironment to promote young-onset colorectal cancer.”
The team also identified over 200 genes that are expressed differently across multiple cell types between early-onset and average-onset tumor samples. Many of these genes are known to be involved with the transition of tumor cells from stationary to acquiring properties that enable spread. This transition, the epithelial-mesenchymal transition, is associated with higher rates of metastatic disease and poorer prognosis, both of which are seen in early-onset cases.
The team also found more long non-coding RNAs in early-onset tumors. Long non-coding RNAs can regulate gene expression, however little is known about the function of many of these strands of RNA.
“Many of the long non-coding RNAs that showed gene expression differences between younger and older patients have not been previously characterized, so we don’t know what they are doing,” says Ng, who is partnering with colleague Marios Giannakis, MD, PhD, to better understand their function.
Future research
In addition to uncovering differences in cell types involved in early-onset colorectal cancer, the team also noted more interactions between stromal cells and immune cells. Ng and collaborators want to learn more about these interactions.
“Up until now, we were frustrated by not being able to identify the biological differences between young-onset and older-onset patients,” says Ng. “Now we know that a key area of focus should be on stromal cells and immune cells to help us better understand early-onset colorectal cancer.”
Written by: Beth Dougherty
Medically Reviewed By: Kimmie Ng, MD. MPH
